The first line therapy for intermediate/ high risk patients with advanced renal cell carcinoma according to therapeutic program B.10

The purpose of this article is to discuss the use of therapeutic options for the first-line systemic treatment of patients with advanced renal cell carcinoma under the B.10 drug program effective in Poland as of May 2022 - with a focus on intermediate and high-risk patient populations according to the IMDC. The specific situation created by reimbursement conditions with the exclusion of regimens combined with a tyrosine kinase inhibitor and immune checkpoint inhibitors along with the marginalisation of the use of an mTOr inhibitor necessitates a choice between two-drug immunotherapy or an antian giogenic drug in monotherapy. In this context, choosing the right treatment in the context of specific clinical situations is a challenge.